Procept Bio Robotics Corp PRCT
We take great care to ensure that the data presented and summarized in this overview for PROCEPT BioRobotics Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRCT
View all-
Vanguard Group Inc Valley Forge, PA5.14MShares$289 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$196 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY1.75MShares$98.7 Million0.05% of portfolio
-
Loomis Sayles & CO L P1.21MShares$68 Million0.12% of portfolio
-
State Street Corp Boston, MA1.19MShares$66.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.16MShares$65.5 Million0.01% of portfolio
-
Franklin Resources Inc San Mateo, CA1.07MShares$60.4 Million0.03% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD986KShares$55.5 Million0.05% of portfolio
-
Morgan Stanley New York, NY757KShares$42.6 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD714KShares$40.2 Million0.01% of portfolio
Latest Institutional Activity in PRCT
Top Purchases
Top Sells
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Insider Transactions at PRCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 18
2025
|
Kevin Waters EVP, CFO |
SELL
Open market or private sale
|
Direct |
733
-0.67%
|
$41,781
$57.06 P/Share
|
|
Mar 18
2025
|
Reza Zadno President, CEO |
SELL
Open market or private sale
|
Direct |
5,475
-3.07%
|
$312,075
$57.06 P/Share
|
|
Mar 18
2025
|
Hisham Shiblaq EVP, Chief Comm. Officer |
SELL
Open market or private sale
|
Direct |
247
-0.39%
|
$14,079
$57.06 P/Share
|
|
Mar 18
2025
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
SELL
Open market or private sale
|
Direct |
316
-0.51%
|
$18,012
$57.06 P/Share
|
|
Mar 06
2025
|
Hisham Shiblaq EVP, Chief Comm. Officer |
SELL
Open market or private sale
|
Direct |
3,588
-5.36%
|
$218,868
$61.31 P/Share
|
|
Mar 06
2025
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
SELL
Open market or private sale
|
Direct |
3,641
-5.56%
|
$222,101
$61.31 P/Share
|
|
Mar 06
2025
|
Reza Zadno President, CEO |
SELL
Open market or private sale
|
Direct |
15,916
-8.18%
|
$970,876
$61.31 P/Share
|
|
Mar 06
2025
|
Kevin Waters EVP, CFO |
SELL
Open market or private sale
|
Direct |
3,662
-3.26%
|
$223,382
$61.31 P/Share
|
|
Mar 03
2025
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
12,958
+16.53%
|
-
|
|
Mar 03
2025
|
Reza Zadno President, CEO |
BUY
Grant, award, or other acquisition
|
Direct |
41,699
+17.66%
|
-
|
|
Mar 03
2025
|
Kevin Waters EVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
16,290
+12.66%
|
-
|
|
Mar 03
2025
|
Hisham Shiblaq EVP, Chief Comm. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,107
+14.23%
|
-
|
|
Feb 10
2025
|
Frederic H Moll Director |
BUY
Exercise of conversion of derivative security
|
Direct |
32,012
+1.86%
|
$32,012
$1.1 P/Share
|
|
Dec 04
2024
|
Reza Zadno President, CEO |
SELL
Open market or private sale
|
Direct |
26,423
-3.88%
|
$2,563,031
$97.57 P/Share
|
|
Dec 04
2024
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
SELL
Open market or private sale
|
Direct |
28,092
-13.06%
|
$2,724,924
$97.0 P/Share
|
|
Dec 04
2024
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
BUY
Exercise of conversion of derivative security
|
Direct |
28,092
+11.44%
|
$730,392
$26.43 P/Share
|
|
Nov 27
2024
|
Reza Zadno President, CEO |
SELL
Open market or private sale
|
Direct |
26,420
-3.32%
|
$2,589,160
$98.61 P/Share
|
|
Nov 20
2024
|
Reza Zadno President, CEO |
SELL
Open market or private sale
|
Direct |
26,420
-3.91%
|
$2,430,640
$92.94 P/Share
|
|
Nov 13
2024
|
Reza Zadno President, CEO |
SELL
Open market or private sale
|
Direct |
26,420
-2.65%
|
$2,483,480
$94.23 P/Share
|
|
Nov 07
2024
|
Antal Rohit Desai Director |
SELL
Open market or private sale
|
Indirect |
34,000
-4.54%
|
$3,230,000
$95.83 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 95.4K shares |
|---|---|
| Exercise of conversion of derivative security | 560K shares |
| Other acquisition or disposition | 6.58M shares |
|---|---|
| Open market or private sale | 915K shares |